focus -WSS

focus

author：explore 2025-10-02 09:47:34 - browse：99

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Leading voice in opioid treatment defends methadone clinic system

Wikipedia

hotspot

WSS

Leading voice in opioid treatment defends methadone clinic system

UnitedHealth increases loan offers after Change Healthcare outage

Diversifying clinical trials isn't enough to close racial gaps: study

Diversifying clinical trials isn't enough to close racial gaps: study

Future doctors should be trained to promote social change

Cassava reveals details — and problems — with Alzheimer's study

hotspot

focus

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Baby aspirin cuts fat buildup in liver disease patients, in small study

BioMarin wins approval for gene therapy to treat hemophilia A

UnitedHealth increases loan offers after Change Healthcare outage

Medicare details structure of new drug price negotiation program

Health AI adoption puts security, privacy startups on investors' radar

Peter Hotez and the public health issue of online harassment

Intermittent fasting comes with a heart risk? Not so fast

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

hotspot

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Argenx readies a blockbuster opportunity with drug for autoimmune disease

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Biden's order seeks to regulate AI risk without stifling innovation

Senate panel to vote on hospitals, PBMs, prisoner care

Colonoscopy prep: Liquid

Wikipedia

focus

hotspot

hotspot